Toll Free Number -1-844-621-2333 (Mon-Sat 7am EST - 9pm EST)

Eutropin HGH  - Somatropin

Double click on above image to view full picture

Zoom Out
Zoom In

More Views

Eutropin HGH - Somatropin

Be the first to review this product

Starting from $20.00

Quick Overview

Somatropin injection is sterile, non-pyrogenic, white in colour and lyophilized powder that are supplied as a single pack that contains 1 vial of powder that contain Somatropin and 1 single use pre-filled syringe that contains diluent (Metacresol in WFI)

Quantity Strength Price Unit Price
2 Pack 4IU $48.00 $24.00
5 Pack 4IU $115.00 $23.00
10 Pack 4IU $220.00 $22.00
15 Pack 4IU $315.00 $21.00
20 Pack 4IU $400.00 $20.00


Somatropin is a polypeptide hormone of recombinant DNA origin that is produced by RDT (recombinant DNA technology) in the yeast cells. This Somatropin injection has 191 amino acid residues and has a molecular weight of 22125dalton. The sequence of the amino acid is same as that of Human Growth Hormone that originates from pituitary gland.

It is sterile, non-pyrogenic, white, lyophilized powder that is used as subcutaneous injection after reconstitution. Each vial containsSomatropin, glycine, mannitolm monobasic sodium phosphate and dibasic sodium phosphate.

Before reconstitution, the powder or diluent should be stored under refrigeration but is should freeze and is kept below 25°C for 3 months after dispensing.

The diluent is provided so after reconstitution with diluent, it can be stored in refrigerator at 2-8°C up to 21 days. The reconstituted vial should not be freeze.

In case the vial is reconstituted with WFI (water for injection), then only one dose per Somatropin injection should be used.

Write Your Own Review

You're reviewing: Eutropin HGH - Somatropin


The dose for Somatropin injection varies with patients’ requirement and body weight. Those who is having deficiency of Human Growth Hormone, minimum of 0.2 mg and maximum of 0.75 mg should be given subcutaneously or intramuscularly every day. Subcutaneous route is preferred as it is less painful and the patient can learn to inject themselves a home.

In case, the patient respond properly and can tolerate, this dose can be increased to 0.0125 mg/kg/day. However, the patient should not be given high dose initially as it might lead to edema in them.

The patients should administer RDT hormone in the evening as it more beneficial because it mimics the circadian rhythm that leads to increased anabolic response.

When it is given in equally divided dose once in a day against three times in week, this shows increased efficacy in the total weekly dosage of RDT hormone.


Some of the most common side effects shown by the patient after the use of Somatropin include abnormal or decreased touch sensation and bleeding after defecation

Some patient might experience bleeding, blistering, burning, coldness, itching, lumps, pain, redness, infection, inflammation,soreness, ulceration at the site of injection.

Patients might get swelling in their face &lower legs, blood in urine, crawling, itching numbness, crawling, change in skin colour, cold flu like symptom, etc.

Sometimes, the patients might get constipation, cough, confusion, darkened urineand decrease in urine frequency, diarrhoea, dry mouth, fast heartbeat and fever.

The patient might get headache, joint pain, itching, light-coloured stool, light-headedness, loss of appetite, muscle pain, nausea, lower back or side pain, pressure in stomach, rapid weight gain, rectal bleeding, sore throat, stomach bloating, skin rash, running nose, etc.


The patient should always use Somatropin injection only as directed by the doctor.

Somatropin might decrease the insulin sensitivity and there is a chance that previously undiagnosed impaired glucose tolerance and diabetes mellitus may be unmasked during the course of treatment. Therefore, the patient should always monitor their glucose level after taking the treatment with Somatropin.

The patient with pre-existing tumourof growth hormone deficiency should always examine themselves for recurrence of the underlying disease process.

The patient should be monitored carefully for any malignant transformation of skin lesions. When Somatropin is given subcutaneously at the same site after long period of time then tissue atrophy might occur. This can be prevented by rotating the site of injection.